No Data
No Data
IMMUNOTECH-B: 2024 INTERIM REPORT
Eternal Biology-B (06978.HK) announced its interim performance, with a 22.6% year-on-year increase in R&D expenses.
Glory Times August 23rd | Yongtai Biology-B (06978.HK) announced its interim performance, the group's other income increased by approximately RMB 5.533 million for the six months ended June 30, 2023, to approximately RMB 6.526 million for the six months ended June 30, 2024, mainly due to an increase in government grants during the reporting period. The group's R&D expenses increased by approximately RMB 74.3 million for the six months ended June 30, 2023, to approximately RMB 91.1 million for the six months ended June 30, 2024, mainly due to the report.
Express News | Immunotech Biopharm - Hy Loss Attributable RMB92.5 Mln
Express News | Immunotech Biopharm H1 Pretax Profit RMB -92.6 Million
IMMUNOTECH-B: ANNOUNCEMENT OF THE INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
Yongtai Biotechnology-B (06978.HK) held a board of directors meeting on August 23 to consider and approve the mid-term performance.
On August 13th, GeLingHui announced that Yongtai Biology-B (06978.HK) plans to hold a board of directors meeting on August 23, 2024 (Friday) to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending June 30, 2024, including its publication.
No Data
No Data